1. Introduction {#sec1-ijerph-17-03679}
===============

Gout adversely affects joints by the deposition of monosodium urate monohydrate crystals and results in inflammatory arthritis. According to the National Health Research Institutes (NHRI), the prevalence of gout in Taiwan is 4.92%, significantly higher than that in other countries \[[@B1-ijerph-17-03679]\]. Patients with gout frequently suffer from multiple comorbidities, including hypertension (HTN), type II diabetes mellitus (DM), cardiovascular disease (CVD), chronic kidney disease (CKD), inflammation, dyslipidemia, and metabolic syndrome \[[@B2-ijerph-17-03679]\] in combination with Parkinson's disease and pre-eclampsia \[[@B3-ijerph-17-03679]\].

In most countries worldwide, the occurrence of injury has gradually declined. However, injuries in general, increase morbidity and mortality and result in a huge expenditure for health insurance systems \[[@B4-ijerph-17-03679]\]. In Taiwan, the prevalence and incidence of injuries are also decreasing, but they play a major role in contributing to patient death. Injuries can be intentional or unintentional. Risk factors for the occurrence of injuries include chronic diseases (e.g., DM, CKD, orthostatic hypotension, cataracts) and lifestyle factors (e.g., walking stick, sleep duration, mental health) \[[@B5-ijerph-17-03679]\]. However, few studies have investigated the relationship between gout and the occurrence of injury.

Approximately one third of patients with incident gout have a comorbidity at diagnosis, such as DM or CKD \[[@B6-ijerph-17-03679]\]. Patients who have DM with peripheral neuropathy and neuropathic pain may display greater gait variability, contributing to falls and subsequent injuries \[[@B7-ijerph-17-03679]\]. CKD is associated with a decline in muscle mass, strength, and function, and may therefore increase the risk of subsequent injuries \[[@B8-ijerph-17-03679]\]. We hypothesized that the onset of gout would increase the risk of injuries, but few studies exist in this area. Therefore, the present study aimed to investigate whether gout directly increases the risk of injury in the Taiwanese population using the LHID from NHRI. Additionally, we examined if drug intervention lowers the risk of injury.

2. Materials and Methods {#sec2-ijerph-17-03679}
========================

2.1. Data Collection {#sec2dot1-ijerph-17-03679}
--------------------

The LHID, established by the NHRI in Taiwan, collected data from subjects enrolled in the National Health Insurance (NHI) program. This was implemented in 1995. The present study collected data randomly selected from a cohort of 1 million subjects covered by the NHI. No statistical significance was observed in the distributions of age and sex between the cohorts in the LHID and the Taiwan NHI enrollees. The disease and diagnostic codes recorded in the registry of clinical visits and hospital care were based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). To maintain the privacy of subjects involved in the database, NHRI released data with encoded identification numbers; therefore, personnel without authorization were unable to reveal or link any direct information to the enrollees. This study (IRB number: TSGH IRB no. 2-105-05-082) was approved by the Ethics Review Board of the National Defense Medical Center and supervised in accordance with the tenets of the Declaration of Helsinki (1975) and its later amendment (2013). The requirement of informed consent was waived.

2.2. Study Design {#sec2dot2-ijerph-17-03679}
-----------------

To evaluate the risk of injury in patients with gout, an LHID from the year 2005 (LHID 2005) was used. This contained the registration and original claim data of 1,000,000 beneficiaries, randomly sampled from the Registry for Beneficiaries (ID) of the NHIR database from 1 January 2005, to 31 December 2005. Two groups were enrolled, and subjects were divided into those with gout (group CFG) and those without (group C). The inclusion criteria of group CFG were patients aged ≥18 years with a newly confirmed diagnosis of gout (ICD-9-CM 274.XX) between 2000 and 2010 and those visiting outpatient clinics at least thrice a year or hospitalized at least once for a confirmed diagnosis of gout. The year of gout diagnosis served as the index year. Regarding group C, subjects were randomly selected from LHID enrollees without a history of gout and were twice matched with group CFG according to sex, age, and index year. We used 1:2 matching to increase precision and hence power. Exclusion criteria were as follows: confirmed gout before 2000; diagnosis of hyperuricemia before tracking; occurrence of injury before tracking; sex unknown; and age \<18 years. The endpoint was the occurrence of injury before subject withdrawal or the end of the follow-up (31 December 2010). Injuries for outcome measurement were defined as ICD-9-CM 800.XX to 999.XX, which include traffic accidents, accidental falls, and intentional and non-intentional injuries. Codes for the individual injury events includes traffic injuries (ICD-9-CM E800-E849), poisoning (ICD-9-CM E850-E869), falls (ICD-9-CM E880-E888), burns and fires (ICD-9-CM E890-E899), drowning (ICD-9-CM E910), suffocation (ICD-9-CM E911-E915), crushing/cutting/piercing (ICD-9-CM E916-E920), excessive heat (ICD-9-CM E900-E900.9), injury caused by animal (ICD-9-CM E906-E906.9), electric current injury (ICD-9-CM E925-E925.9), other unintentional injuries (ICD-9-CM E870-E879, E900-E909, E951-E949), suicide (ICD-9-CM E950-E959), homicide/abuse (ICD-9-CM E960-E969), and intention unknown (E980-E989). Hazard ratios of various injury causes between groups CFG and C were of great interest and were analyzed. We also used the Injury Severity Score (ISS) to assess the trauma severity of injury. ISS ≥16 is usually classified as major trauma and may result in poorer outcomes.

Confounding factors such as sex, age, comorbidities, resident location, and insurance premium were adjusted accordingly. Individuals with comorbidities before the index date were the study subjects. The comorbidities included diabetes mellitus (DM, ICD-9-CM 250), hypertension (ICD-9-CM 401-405), stroke (ICD-9-CM 430-438), chronic renal disease (CKD, ICD-9-CM 585), coronary artery disease (CAD, ICD-9-CM 410-414), liver cirrhosis (ICD-9-CM 570, 571, 572.1, 572.4, 573.1-573.3), chronic obstructive pulmonary disease (COPD, ICD-9-CM 491, 492, and 496), hyperlipidemia (ICD-9-CM 272.0, 272.2, 272.4), and cancer (ICD-9-CM 140-208). This study also evaluated whether urate-lowering drug intervention or compliance affected the risk of injury, including xanthine oxidase inhibitor allopurinol (Anatomical Therapeutic Chemical (ATC) code M04AA01), febuxostat (ATC code M04AA03), uricosuric agents probenecid (ATC code M04AB01), sulfinpyrazone (ATC code M04AB02), and benzbromarone (ATC code M04AB03)\] as well as the uricase agent rasburicase (ATC code V03AF07). Medication compliance was calculated as the medication possession ratio (MPR; sum of days of supply of urate-lowering drugs divided by following up duration). We identified the good medication adherence subgroup as MPR \> 80%, the intermittent adherence subgroup as MPR between 40% and 80%, and the poor adherence subgroup as MPR \< 40%.

2.3. Data Analysis {#sec2dot3-ijerph-17-03679}
------------------

Continuous variables were expressed as mean ± SD. Normally distributed continuous data between patients with and without gout, were compared by unpaired Student's t-test/one-way ANOVA; nonparametric continuous data were analyzed by the Mann-Whitney U test/Kruskal--Wallis Test. Categorical variables were compared by χ^2^ analysis with Fisher's exact correction. Cumulative risks of injury were calculated using the Kaplan--Meier method, and the differences in survival were determined by the log-rank test. Univariate and multivariable Cox proportional hazard regression analyses were used to determine the impact of gout on the occurrence of injury and identify other independent predictive variables for these events. *p* \< 0.05 was considered statistically significant. The hazard ratios and confidence intervals (95%) from the Cox regression analyses were used as estimates of relative risk.

3. Results {#sec3-ijerph-17-03679}
==========

3.1. Sample Size {#sec3dot1-ijerph-17-03679}
----------------

As showed in [Supplementary Figure S1](#app1-ijerph-17-03679){ref-type="app"}, there was a total of 20,795,043 events from 2000 to 2010 in the Taiwan LHID. Around 986,713 individuals had medical records for visits to outpatient clinics, emergency departments, or hospitalization. Among them, 87,678 were diagnosed with gout, while 1864 were excluded. Overall, the study population totaled 257,442 in this retrospective matched cohort study for analysis, including 85,814 patients with gout (group CFG) and 171,628 without (group C). The incidences of injury in groups CFG and C were 18.92% and 17.83%, respectively, with significant differences (*p* \< 0.001) in these two groups, as shown in [Figure 1](#ijerph-17-03679-f001){ref-type="fig"}. Therefore, patients with gout had a higher risk of injury.

3.2. Baseline Characteristics {#sec3dot2-ijerph-17-03679}
-----------------------------

[Table 1](#ijerph-17-03679-t001){ref-type="table"} presents demographics and comorbidities of groups CFG and C at the end of follow-up. The proportion of comorbidities, including DM, HTN, stroke, CKD, and coronary artery disease (CAD), was higher in group CFG than in group C (*p* \< 0.001). Additionally, group CFG had a higher proportion of the population living in Central, Southern, and Eastern Taiwan, as well as in the outlying islands than group C (*p* \< 0.001). Group CFG had a higher proportion in insurance premiums segment NT \$15,841--25,000 than group C (*p* = 0.001).

3.3. Differences in Injuries between Groups CFG and C at the End of Follow-Up {#sec3dot3-ijerph-17-03679}
-----------------------------------------------------------------------------

[Table 2](#ijerph-17-03679-t002){ref-type="table"} shows that the risk of injuries in group CFG was significantly higher at the end of follow-up (*p* \< 0.001). Further analysis showed that the primary causes of classifiable injuries in both groups were falls, traffic injuries, and other unintentional injuries. In addition, group CFG suffered a more significant proportion of severe trauma when injury occurred (*p* \< 0.001).

3.4. Risk Factors for the Occurrence of Injuries {#sec3dot4-ijerph-17-03679}
------------------------------------------------

As shown in [Table 3](#ijerph-17-03679-t003){ref-type="table"}, after variable adjustment, group CFG had a graver risk of injury (2034 times higher; *p* \< 0.001). In addition, subjects with chronic renal disease displayed an enhanced risk of injury (1302 times higher; *p* \< 0.001). Furthermore, subjects living in Central, Southern, and Eastern Taiwan, as well as in the outlying islands had a more significant risk of injury than those living in Northern Taiwan (1169--1201 times higher; *p* \< 0.001). However, other chronic disease, such as diabetes mellitus, hypertension, stroke, or coronary artery disease, were not a significant risk factor of injury in our study.

3.5. Factors for the Occurrence of Injuries by Cox Regression Analysis {#sec3dot5-ijerph-17-03679}
----------------------------------------------------------------------

A stratified analysis of multiple variables performed to detect the risk of injury in the two groups is shown in [Table 4](#ijerph-17-03679-t004){ref-type="table"}. No statistical difference was found in the male (*p* \< 0.001) and female (*p* \< 0.001) groups, demonstrating that regardless of sex, the risk of injury was higher in group CFG. Similarly, the risk of injury was higher in group CFG than in group C with or without DM, HTN, stroke, CKD, or CAD (*p* \< 0.001).

Additionally, regardless of the season, resident location, or insurance premium, the risk of injury was higher in group CFG (*p* \< 0.001). Thus, people with gout had a higher association with the occurrence of injury, independent of other factors.

3.6. Relationship between the Occurrence of Subgroup Injuries and Gout {#sec3dot6-ijerph-17-03679}
----------------------------------------------------------------------

By performing an analysis of subgroups of injury at the end of the follow-up in [Table 5](#ijerph-17-03679-t005){ref-type="table"}, it was found that group CFG had an enhanced risk of traffic injuries, (1575 times higher), poisoning (1650 times higher), falls (1743 times higher), crushing/cutting/piercing (1879 times higher), suicide (1506 times higher), other unintentional injuries (1511 times higher), and not-provided E-code (1473 times higher) compared to group C (*p* \< 0.001).

3.7. Difference in the Occurrence of Injuries in Group CFG with Medication (M) and without Medication (NM) {#sec3dot7-ijerph-17-03679}
----------------------------------------------------------------------------------------------------------

Group CFG was separated into two subgroups, those with medication (M) and those without medication (NM), as shown in [Supplementary Figure S2](#app1-ijerph-17-03679){ref-type="app"}. The incidence of injury was 18.76% in subgroup CFG-M and 19.96% in group CFG-NM, without significant differences (*p* = 0.232) between the two groups, as shown in [Figure 2](#ijerph-17-03679-f002){ref-type="fig"}A. Group CFG-M was separated into three subgroups using the medication possession ratio (MPR): the incidence of injury in the poor adherence subgroup was 17.00%; in the intermittent adherence subgroup, 20.17%; and in the good adherence subgroup, 19.03%. No significant differences (*p* = 0.371) were found between the three groups in [Figure 2](#ijerph-17-03679-f002){ref-type="fig"}B.

4. Discussion {#sec4-ijerph-17-03679}
=============

To the best of our knowledge, this is the first national population-based cohort study to establish a substantial association between gout and injury. This study confirmed that patients with gout experienced an increased risk of injury. According to our data, four issues were highlighted: first, the enrollment of patients with gout was affected by significant parameters, such as residence, insurance premium, and comorbidity with other chronic diseases; second, risk factors for the occurrence of injuries in Taiwan include gout, chronic renal disease, and resident location; third, in patients with gout, there was a greater incidence of injuries such as traffic injury, falls, and other unintentional injuries; and finally, the intervention of urate-lowering drugs for patients with gout did not lower the risk of the injuries.

In the demographic data, subjects diagnosed with gout in Taiwan displayed significant parameters, such as resident location, insurance premium, and a higher proportion of other chronic diseases. In the Korea multicenter study, summer is the most common season of gout onset \[[@B9-ijerph-17-03679]\]. Similarly, a retrospective study in the United Kingdom found that the incidence of gout increased from April to September \[[@B10-ijerph-17-03679]\]. In the present study, gout attacks were found to occur particularly in summer and autumn. Regarding the seasonality of gout, previous evidence has proposed seasonal variations of urate, with higher serum levels during the summer months \[[@B11-ijerph-17-03679]\]. Changes in diet and increased alcohol consumption, enhanced physical activity and body temperature resulting in dehydration status, may contribute to the development of gout during this period. Regarding location, evidence from Taiwan has suggested that the development of gout maintains regional differences, particularly in the eastern coastal and offshore islands \[[@B12-ijerph-17-03679]\]. In the present study, similar findings were presented. A greater incidence of gout was determined particularly in central, southern, and eastern areas and in the outlying islands of Taiwan. As for chronic disease, in the present study, subjects with gout had a significantly higher risk of developing other comorbidities, including DM, HTN, stroke, and CAD. The results were compatible with previous findings from in vivo and in vitro studies, suggesting a strong association with serum uric acid levels, cardiovascular diseases, CKD, and stroke \[[@B13-ijerph-17-03679],[@B14-ijerph-17-03679]\]. Hyperuricemia may induce oxidative stress \[[@B15-ijerph-17-03679]\], stimulate an inflammatory response \[[@B16-ijerph-17-03679]\], and cause endothelial dysfunction \[[@B17-ijerph-17-03679]\]. A recent study also revealed a connection between hyperuricemia and an increased risk of cardiovascular mortality \[[@B18-ijerph-17-03679]\]. In summary, findings in subjects in group CFG display unique correlations with season, residence, and comorbidities; physicians should be alert to these associations when treating patients with hyperuricemia and gout.

In the present study, demographic data and morbidities were analyzed for relationships with the occurrence of injury. The incidence of injury was significantly correlated with patients with gout in terms of chronic renal disease and resident location. Gout is usually associated with long-lasting, abnormally high amounts of uric acid in the blood. It is a painful condition involving the joints, like arthritis. Therefore, a sudden onset of gout may cause gait instability, contributing to falls and subsequent injuries. Another condition, chronic progressive tophaceous arthritis, also causes joint damage, bone destruction and deformity, and may increase the risk of subsequent injuries \[[@B19-ijerph-17-03679]\]. Regarding renal disease, injury from falls has been proven to be associated with CKD, particularly in elderly patients undergoing hemodialysis \[[@B20-ijerph-17-03679]\]. Polypharmacy, anemia, vitamin D deficiency, sarcopenia, fluid status change, and posture hypotension all potentially contribute to the higher incidence of injury in this group. As we did not further classify the stages of renal diseases in this study, an additional large cohort study is needed to analyze the relationship between CKD stages and the occurrence of injury. Furthermore, regarding resident location, a previous study suggested a significant association among health, lifestyle, and behavior with the development of injury \[[@B21-ijerph-17-03679]\]. An inconvenient living environment and poorer medical care is associated with an elevated incidence of injury. Our findings confirmed that location is a risk factor for the occurrence of gout and injuries.

Among the causes of injury, we found that traffic, poisoning, falls, crushing, cutting, piercing, other unintentional injuries, and suicides were significantly higher in people with gout. Patients with gout may display a significant decrease in walking velocity, cadence, and stride length during periods of joint pain. Antalgic gait may increase the risk of traffic injury and falls. When chronic tophi affect the movement and flexibility of the joints, the risk of cutting, piercing, and crushing may also increase. In addition, steroid treatment for gout may induce muscle weakness and osteoporosis and increase the incidence of injury. A recent meta-analysis demonstrated a strong positive relationship between gout and depression \[[@B22-ijerph-17-03679]\]. We can reasonably speculate that the greater incidence of suicide and poisoning in gout patients is related to depressive disorders. Our findings emphasize the importance of developing national preventive programs designed to reduce the incidence of injury in patients with gout based on the risk factors.

Intervention with drugs in patients with gout did not lower the risk of injury. Hyperuricemia is the underlying condition accelerating gout and the long-term treatment of it involves the therapeutic lowering of serum and tissue uric acid levels. In 2012, the American College of Rheumatology published its first treatment guidelines. It reasserted that chronic gout needed persistent treatment, and integrated the issues of anti-inflammation, urate-lowering therapy (ULT), and lifestyle risk management \[[@B23-ijerph-17-03679]\]. However, in the present study, drug intervention with ULT and drug compliance did not lower the risk of injury in this group. There is a possibility that when subjects were diagnosed with gout, they had already suffered irreversible joint damage because of long-term hyperuricemia-associated comorbidities. After the occurrence of unexpected events, the treatment for gout was inadequate. Further strict randomized control trials are required to explore the real connection and impacts.

There are some limitations to our study. First, the NHIR database does not provide personal history and lifestyle information of patients, such as smoking, drinking, body mass index, and functional capacity. These are the potential confounding factors for this study. In addition, all definitions of variables were based on clinical physicians' diagnosis and coding; therefore, any misidentification may result in study bias. Second, people with hypertension, diabetes mellitus, stroke, and coronary artery disease did not show an elevated risk of injuries in our studies. This result is unexpected and may differ from previous studies. We believe that this result requires further analysis of the injury subgroup to confirm these findings. Third, we did not analyze the type of medication used in the study or in the comparison cohort due to technical limitations for data retrieval. In addition, we could not evaluate the severity of gout or the interaction with medication use. Fourth, we did not analyze the multiple injury events, which is an important issue in epidemiology studies. Lastly, most injury severity data are unavailable in the NHIR database. Although ISS ≥16 points was employed as the basis to present the severity of patients with trauma, not every injury event was scored.

5. Conclusions {#sec5-ijerph-17-03679}
==============

Physicians and government policymakers should remain alert to the risk of injury in patients with gout and initiate early therapeutic strategies. The present national population-based cohort study supports the view that gout may directly increase the risk of injury. Although urate-lowing drug intervention did not curtail the incidence of injury in the present study, further research is required to clarify this finding.

The following are available online at <https://www.mdpi.com/1660-4601/17/10/3679/s1>, Figure S1: Flowchart of enrollment of patients with gout (group CGF), matched with those without gout (group C), Figure S2: Flowchart of enrollment of injured patients on medication and those without medication.
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###### 

Demographic and Comorbidities of Patients with Gout (Group CFG) and Without (Group C).

                                      Gout            Total           Group CFG       Group C   *p* Value           
  ----------------------------------- --------------- --------------- --------------- --------- ----------- ------- ---------
  **Total**                           257,442                         85,814          33.33     171,628     66.67   
  **Sex**                                                                                                           0.999
  Male                                206,907         80.37           68,969          80.37     137,938     80.37   
  Female                              50,535          19.63           16,845          19.63     33,690      19.63   
  **Age (Years) (Mean ± SD)**         64.15 ± 16.69   63.90 ± 16.13   64.28 ± 16.97   0.041                         
  **Season**                                                                                                        \<0.001
  Spring (March--May)                 62,939          24.45           19,672          22.92     43,267      25.21   
  Summer (June--August)               64,590          25.09           21,974          25.61     42,616      24.83   
  Autumn (September--November)        68,327          26.54           24,952          29.08     43,375      25.27   
  Winter (December--February)         61,586          23.92           19,216          22.39     42,370      24.69   
  **Location**                                                                                                      \<0.001
  Northern Taiwan                     101,639         39.48           32,547          37.93     69,092      40.26   
  Central Taiwan                      73,304          28.47           24,929          29.05     48,375      28.19   
  Southern Taiwan                     64,734          25.15           21,637          25.21     43,097      25.11   
  Eastern Taiwan                      16,564          6.43            6208            7.23      10,356      6.03    
  Outlying islands                    1201            0.47            493             0.57      708         0.41    
  **Insured Premium (NT\$)**                                                                                        0.001
  \<15,840                            253,900         98.62           84,517          98.49     169,383     98.69   
  15,841--25,000                      2832            1.10            1077            1.26      1755        1.02    
  ≥25,001                             710             0.28            220             0.26      490         0.29    
  **Diabetes Mellitus (DM)**                                                                                        \<0.001
  Without                             212,846         82.68           69,797          81.34     143,049     83.35   
  With                                44,596          17.32           16,017          18.66     28,579      16.65   
  **Hypertension**                                                                                                  \<0.001
  Without                             197,472         76.71           56,906          66.31     140,566     81.90   
  With                                59,970          23.29           28,908          33.69     31,062      18.10   
  **Stroke**                                                                                                        \<0.001
  Without                             233,003         90.51           77,098          89.84     155,905     90.84   
  With                                24,441          9.49            8718            10.16     15,723      9.16    
  **Chronic Renal Disease**                                                                                         \<0.001
  Without                             248,622         96.57           82,486          96.12     166,136     96.80   
  With                                8820            3.43            3328            3.88      5492        3.20    
  **Coronary Artery Disease (CAD)**                                                                                 \<0.001
  Without                             230,456         89.52           75,336          87.79     155,120     90.38   
  With                                26,986          10.48           10,478          12.21     16,508      9.62    

*p*-value (category variable: Chi-square/Fisher's exact test; continue variable: independent t-test); DM: ICD-9-CM 250; Hypertension: ICD-9-CM 401-405; Stroke: ICD-9-CM 430-438; Chronic renal disease: ICD-9-CM 585; CAD: ICD-9-CM 410-414.
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###### 

Differences in Injuries between Patients with Gout (Group CFG) and Without (Group C).

                                         Gout      Total   Group CFG   Group C   *p* Value           
  -------------------------------------- --------- ------- ----------- --------- ----------- ------- ---------
  **Total**                              257,442           85,814      33.33     171,628     66.67   
  **Injury**                                                                                         \<0.001
  Without                                210,610   81.81   69,576      81.08     141,034     82.17   
  With                                   46,832    18.19   16,238      18.92     30,594      17.83   
  **Cause of injury**                                                                                \<0.001
  Traffic Injuries                       6615      14.12   2141        13.19     4474        14.62   
  Poisoning                              586       1.25    234         1.44      352         1.15    
  Falls                                  10,044    21.45   3322        20.46     6722        21.97   
  Burns and Fires                        73        0.16    19          0.12      54          0.18    
  Drowning                               9         0.02    3           0.02      6           0.02    
  Suffocation                            217       0.46    68          0.42      149         0.49    
  Crushing/Cutting/Piercing              1452      3.10    512         3.15      940         3.07    
  Excessive Heat                         12        0.03    4           0.02      8           0.03    
  Injury Caused by Animals               96        0.03    44          0.05      52          0.03    
  Electric Current Injury                21        0.04    4           0.02      17          0.06    
  Other Unintentional Injuries           9472      20.23   3768        23.20     5704        18.64   
  Suicide                                555       1.19    179         1.10      376         1.23    
  Homicide/Abuse                         449       0.96    140         0.86      309         1.01    
  Intention Unknown                      305       0.65    110         0.68      195         0.64    
  No Provided E-Code                     16,926    36.14   5690        35.04     11,236      36.73   
  **Injury Severity Score (ISS) ≥ 16**                                                               \<0.001
  Without                                257,056   99.85   85,631      99.79     171,425     99.88   
  With                                   386       0.15    183         0.21      203         0.12    

*p*-value (category variable: Chi-square/Fisher's exact test; continue variable: independent t-test).
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###### 

Risk Factors for the Occurrence of Injuries.

  Variables                           Crude HR    95% CI   95% CI   *p*       Adjusted HR   95% CI   95% CI   *p*
  ----------------------------------- ----------- -------- -------- --------- ------------- -------- -------- ---------
  **Gout**                                                                                                    
  Without                             Reference                               Reference                       
  With                                1.992       1.953    2.031    \<0.001   2.034         1.995    2.074    \<0.001
  Sex                                                                                                         
  Male                                0.912       0.892    0.932    \<0.001   0.889         0.869    0.909    \<0.001
  Female                              Reference                               Reference                       
  **Age (Years)**                     0.989       0.988    0.990    \<0.001   0.993         0.992    0.994    \<0.001
  **Diabetes Mellitus (DM)**                                                                                  
  Without                             Reference                               Reference                       
  With                                0.856       0.836    0.876    \<0.001   0.894         0.873    0.916    \<0.001
  **Hypertension**                                                                                            
  Without                             Reference                               Reference                       
  With                                0.751       0.735    0.768    \<0.001   0.787         0.769    0.806    \<0.001
  **Stroke**                                                                                                  
  Without                             Reference                               Reference                       
  With                                0.618       0.596    0.642    \<0.001   0.649         0.626    0.674    \<0.001
  **Chronic Renal Disease**                                                                                   
  Without                             Reference                               Reference                       
  With                                1.484       1.422    1.548    \<0.001   1.302         1.247    1.360    \<0.001
  **Coronary Artery Disease (CAD)**                                                                           
  Without                             Reference                               Reference                       
  With                                0.612       0.592    0.633    \<0.001   0.661         0.639    0.685    \<0.001
  **Season**                                                                                                  
  Spring (March--May)                 Reference                               Reference                       
  Summer (June--August)               0.944       0.920    0.968    \<0.001   0.932         0.909    0.956    \<0.001
  Autumn (September--November)        0.813       0.792    0.834    \<0.001   0.803         0.783    0.824    \<0.001
  Winter (December--February)         0.911       0.887    0.935    \<0.001   0.919         0.896    0.943    \<0.001
  **Location**                                                                                                
  Northern Taiwan                     Reference                               Reference                       
  Central Taiwan                      1.228       1.201    1.256    \<0.001   1.169         1.143    1.196    \<0.001
  Southern Taiwan                     1.215       1.186    1.243    \<0.001   1.184         1.156    1.212    \<0.001
  Eastern Taiwan                      1.314       1.268    1.361    \<0.001   1.201         1.159    1.245    \<0.001
  Outlying Islands                    1.313       1.156    1.492    \<0.001   1.174         1.033    1.334    0.014
  **Insured premium (NT\$)**                                                                                  
  \<15,840                            Reference                               Reference                       
  15,841--25,000                      0.980       0.903    1.063    0.622     0.899         0.828    0.975    0.010
  ≥25,001                             0.718       0.572    0.902    0.004     0.622         0.495    0.782    \<0.001

HR = hazard ratio, CI = confidence interval, Adjusted HR: Adjusted variables listed in [Table 1](#ijerph-17-03679-t001){ref-type="table"}. DM: ICD-9-CM 250; Hypertension: ICD-9-CM 401-405; Stroke: ICD-9-CM 430-438; Chronic renal disease: ICD-9-CM 585; CAD: ICD-9-CM 410-414.

ijerph-17-03679-t004_Table 4

###### 

Factors for the Occurrence of Injuries Stratified by Variable Listed in [Table 1](#ijerph-17-03679-t001){ref-type="table"} by Cox Regression Analysis.

                                      Gout     Group CFG    Group C     Ratio    Adjusted HR   95%CI       95%CI   *p*                     
  ----------------------------------- -------- ------------ ----------- -------- ------------- ----------- ------- ------- ------- ------- ----------
  **Total**                           16,238   150,342.08   10,800.70   30,594   322,350.39    9490.91     1.138   2.034   1.995   2.074   \<0.0011
  **Sex**                                                                                                                                  
  Male                                12,534   118,736.14   10,556.18   23,960   256,463.93    9342.44     1.130   2.021   1.976   2.066   \<0.001
  Female                              3704     31,605.94    11,719.32   6634     65,886.46     10,068.84   1.164   2.077   1.993   2.165   \<0.001
  **Diabetes mellitus (DM)**                                                                                                               
  Without                             13,201   116,597.02   11,321.90   24,862   254,643.69    9763.45     1.160   2.082   2.037   2.127   \<0.001
  With                                3037     33,745.06    8999.84     5732     67,706.70     8465.93     1.063   1.834   1.753   1.919   \<0.001
  **Hypertension**                                                                                                                         
  Without                             11,736   98,684.39    11,892.46   24,703   238,757.71    10,346.47   1.149   2.000   1.955   2.045   \<0.001
  With                                4502     51,657.69    8715.06     5891     83,592.68     7047.27     1.237   2.184   2.097   2.274   \<0.001
  **Stroke**                                                                                                                               
  Without                             15,258   134,176.20   11,371.61   28,531   284,544.60    10,026.90   1.134   2.060   2.019   2.103   \<0.001
  With                                980      16,165.88    6062.15     2063     37,805.79     5456.84     1.111   1.667   1.542   1.802   \<0.001
  **Chronic renal disease**                                                                                                                
  Without                             15,325   143,313.20   10,693.36   29,281   307,574.55    9519.97     1.123   2.076   2.035   2.119   \<0.001
  With                                913      7028.89      12,989.25   1313     14,775.84     8886.13     1.462   1.492   1.368   1.627   \<0.001
  **Coronary artery disease (CAD)**                                                                                                        
  Without                             14,873   129,957.13   11,444.54   28332    284,501.30    9958.48     1.149   2.039   1.998   2.082   \<0.001
  With                                1365     20,384.95    6696.12     2262     37,849.09     5976.37     1.120   1.940   1.810   2.079   \<0.001
  **Season**                                                                                                                               
  Spring (March--May)                 3967     33,203.35    11,947.59   7760     75,299.86     10,305.46   1.159   2.061   1.981   2.143   \<0.001
  Summer (June--August)               4271     37,283.12    11,455.59   7792     80,649.66     9661.54     1.186   2.096   2.016   2.178   \<0.001
  Autumn (September--November)        4326     45,283.44    9553.16     7590     89,206.10     8508.39     1.123   1.985   1.910   2.063   \<0.001
  Winter (December--February)         3674     34,572.18    10,627.04   7452     77,194.77     9653.50     1.101   1.999   1.919   2.082   \<0.001
  **Location**                                                                                                                             
  Northern Taiwan                     5326     55,338.61    9624.38     10,761   127,610.68    8432.68     1.141   2.074   2.004   2.145   \<0.001
  Central Taiwan                      5147     44,678.27    11,520.14   9259     91,204.09     10,151.96   1.135   2.082   2.010   2.156   \<0.001
  Southern Taiwan                     4277     37,643.40    11,361.89   8075     79,540.46     10,152.07   1.119   1.967   1.894   2.043   \<0.001
  Eastern Taiwan                      1391     11,782.55    11,805.59   2357     21,562.39     10,931.07   1.080   1.932   1.804   2.069   \<0.001
  Outlying Islands                    97       899.26       10,786.65   142      2432.78       5836.94     1.848   1.779   1.358   2.330   \<0.001
  **Insured premium (NT\$)**                                                                                                               
  \<15,840                            15,975   147,884.48   10,802.35   30,197   317,543.94    9509.55     1.136   2.029   1.989   2.069   \<0.001
  15,841--25,000                      238      2122.27      11,214.41   348      4087.90       8512.93     1.317   2.539   2.136   3.020   \<0.001
  ≥25,001                             25       335.33       7455.34     49       718.56        6819.19     1.093   2.946   1.695   5.121   \<0.001

PYs = Person-years; Adjusted HR = Adjusted Hazard ratio: Adjusted for variables listed in Cox Regression; CI = confidence interval; DM: ICD-9-CM 250; Hypertension: ICD-9-CM 401-405; Stroke: ICD-9-CM 430-438; Chronic renal disease: ICD-9-CM 585; CAD: ICD-9-CM 410-414.

ijerph-17-03679-t005_Table 5

###### 

Relationship between the Occurrence of Subgroup Injuries in Patients with Gout (Group CFG) and Without Gout (Group C).

                                        Gout     Group CFG    Group C     Ratio    Adjusted HR   95%CI      95%CI   *p*                     
  ------------------------------------- -------- ------------ ----------- -------- ------------- ---------- ------- ------- ------- ------- ---------
  **Total**                             16,238   150,342.08   10,800.70   30,594   322,350.39    9,490.91   1.138   2.034   1.995   2.074   \<0.001
  **Cause of injury**                                                                                                                       
  Traffic injuries                      2141     150,342.08   1424.09     4,74     322,350.39    1387.93    1.026   1.575   1.494   1.861   \<0.001
  Poisoning                             234      150,342.08   155.65      352      322,350.39    109.20     1.425   1.650   1.382   1.970   \<0.001
  Falls                                 3322     150,342.08   2209.63     6722     322,350.39    2085.31    1.060   1.743   1.670   1.820   \<0.001
  Burns and fires                       19       150,342.08   12.64       54       322,350.39    16.75      0.754   0.637   0.215   8.189   0.721
  Drowning                              3        150,342.08   2.00        6        322,350.39    1.86       1.072   1.022   0.674   3.571   0.166
  Suffocation                           68       150,342.08   45.23       149      322,350.39    46.22      0.979   0.942   0.328   2.554   0.402
  Crushing/Cutting/Piercing             512      150,342.08   340.56      940      322,350.39    291.61     1.168   1.879   1.662   2.123   \<0.001
  Excessive Heat                        4        150,342.08   2.66        8        322,350.39    2.48       1.072   1.145   0.976   2.447   0.435
  Injury Caused by Animals              44       150,342.08   29.27       52       322,350.39    16.13      1.814   1.976   1.013   3.001   0.026
  Electric Current Injury               4        150,342.08   2.66        17       322,350.39    5.27       0.504   0.976   0.432   1.434   0.556
  Other Unintentional Injuries          3768     150,342.08   2506.28     5704     322,350.39    1769.50    1.416   1.511   1.126   2.138   \<0.001
  Suicide                               179      150,342.08   119.06      376      322,350.39    116.64     1.021   1.506   1.247   1.820   \<0.001
  Homicide/Abuse                        140      150,342.08   93.12       309      322,350.39    95.86      0.971   0.618   0.301   1.012   0.058
  Intention Unknown                     110      150,342.08   73.17       195      322,350.39    60.49      1.209   1.447   1.119   1.876   0.005
  No Provided E-Code                    5690     150,342.08   3784.70     11,236   322,350.39    3485.65    1.086   1.473   1.426   1.552   \<0.001
  **Injury Severity Score (ISS) ≥16**                                                                                                       
  Without                               16,055   150,342.08   10,678.98   30,391   322,350.39    9427.94    1.133   2.025   1.986   2.066   \<0.001
  With                                  183      150,342.08   121.72      203      322,350.39    62.97      1.933   2.114   1.692   2.641   \<0.001

PYs = Person-years; Adjusted HR = Adjusted Hazard ratio: Adjusted for the variables listed in Cox regression in [Table 1](#ijerph-17-03679-t001){ref-type="table"}; CI = confidence interval.
